Five days following tumor implantation, AAV6 encoding CXCL9 or EGFP control transgene was injected intratumorally, with anti-PD-1 ICB (10 mg/kg) administered intraperitoneally for a total of 4 doses given every 72 h (Fig. 3d). This evidence concerns the gene CXCL9 and neoplasm.